Previous studies found a central role for epidermal growth factor receptor (EGFR), mesenchymal-epithelial transition factor (MET) and insulin-like growth factor 1 receptors (IGFR1) in abolishing RAF inhibitor sensitivity in colorectal cancer and melanoma with BRAFV600E 18-22. Here, EGFR is linked to melanoma.